Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 3 de 3
Filtrar
Más filtros











Base de datos
Intervalo de año de publicación
1.
Inflammation ; 47(2): 609-625, 2024 Apr.
Artículo en Inglés | MEDLINE | ID: mdl-38448631

RESUMEN

Siglec-9/E is a cell surface receptor expressed on immune cells and can be activated by sialoglycan ligands to play an immunosuppressive role. Our previous study showed that increasing the expression of Siglec-9 (the human paralog of mouse Siglec-E) ligands maintains functionally quiescent immune cells in the bloodstream, but the biological effects of Siglec-9 ligand alteration on atherogenesis were not further explored. In the present study, we demonstrated that the atherosclerosis risk factor ox-LDL or a high-fat diet could decrease the expression of Siglec-9/E ligands on erythrocytes. Increased expression of Siglec-E ligands on erythrocytes caused by dietary supplementation with glucose (20% glucose) had anti-inflammatory effects, and the mechanism was associated with glucose intake. In high-fat diet-fed apoE-/- mice, glucose supplementation decreased the area of atherosclerotic lesions and peripheral inflammation. These data suggested that increased systemic inflammation is attenuated by increasing the expression of Siglec-9/E ligands on erythrocytes. Therefore, Siglec-9/E ligands might be valuable targets for atherosclerosis therapy.


Asunto(s)
Antígenos de Diferenciación de Linfocitos B , Dieta Alta en Grasa , Eritrocitos , Glucosa , Inflamación , Lectinas Similares a la Inmunoglobulina de Unión a Ácido Siálico , Animales , Dieta Alta en Grasa/efectos adversos , Lectinas Similares a la Inmunoglobulina de Unión a Ácido Siálico/metabolismo , Ratones , Inflamación/metabolismo , Eritrocitos/metabolismo , Eritrocitos/efectos de los fármacos , Ligandos , Glucosa/metabolismo , Aterosclerosis/metabolismo , Aterosclerosis/prevención & control , Antígenos CD/metabolismo , Suplementos Dietéticos , Masculino , Ratones Endogámicos C57BL
2.
Oncogene ; 42(34): 2547-2557, 2023 08.
Artículo en Inglés | MEDLINE | ID: mdl-37443303

RESUMEN

Rho GTPase-activating protein 4 (ARHGAP4) is an important Rho family GTPase-activating protein that is strongly associated with the onset and progression of some tumors. We found that ARHGAP4 mRNA and protein are overexpressed in human acute myeloid leukemia (AML) patients and are associated with a poor prognosis. ARHGAP4 knockdown significantly impairs viability and colony formation capacity and induces apoptosis in AML cells. Further results demonstrate that ARHGAP4 deletion impairs AML progression in vivo. Interestingly, DRAM1 signaling is significantly activated in AML cells with ARHGAP4 knockdown. Our results also indicated that ARHGAP4 might function in AML cells by binding with p53 to inhibit DRAM1. Moreover, knockdown of DRAM1 rescues the defects of ARHGAP4 in AML cells. This newly described role of the ARHGAP4/DRAM1 axis in regulating AML progression may have important therapeutic implications.


Asunto(s)
Leucemia Mieloide Aguda , Humanos , Apoptosis , Línea Celular Tumoral , Proliferación Celular , Proteínas Activadoras de GTPasa/genética , Leucemia Mieloide Aguda/patología , Proteínas de la Membrana/genética , ARN Mensajero , Transducción de Señal
3.
Pathol Res Pract ; 245: 154483, 2023 May.
Artículo en Inglés | MEDLINE | ID: mdl-37120908

RESUMEN

BACKGROUND: Acute myeloid leukemia (AML) is a type of hematological tumor caused by malignant clone hematopoietic stem cells. The relationship between lncRNAs and tumor occurrence and progression has been gaining attention. Research has shown that Smooth muscle and endothelial cell-enriched migration/differentiation-associated lncRNA (SENCR) is abnormally expressed in various diseases, whereas its role in AML is still poorly understood. METHODS: The expression of SENCR, microRNA-4731-5p (miR-4731-5p) and Interferon regulatory factor 2 (IRF2) were measured using qRT-PCR. The proliferation, cycle and apoptosis of AML cells with or without knockdown of SENCR were detected by CCK-8 assay, EdU assay, flow cytometry, western blotting and TUNEL assay, respectively. Consistently, SENCR knockdown was impaired the AML progression in immunodeficient mice. In addition, the binding of miR-4731-5p to SENCR or IRF2 was confirmed by luciferase reporter genes assay. Finally, rescue experiments were conducted to confirm the role of SENCR/miR-4731-5p/IRF2 axis in AML. RESULTS: SENCR is highly expressed in AML patients and cell lines. The patients with high SENCR expression had poorer prognosis compared with those with low SENCR expression. Interestingly, knockdown of SENCR inhibits the growth of AML cells. Further results demonstrated that the reduction of SENCR slows the progression of AML in vivo. SENCR could function as a competing endogenous RNA (ceRNA) to negatively regulate miR-4731-5p in AML cells. Furthermore, IRF2 was validated as a direct target gene of miR-4731-5p in AML cells. CONCLUSIONS: Our findings underscore the important role of SENCR in regulating the malignant phenotype of AML cells by targeting the miR-4731-5p/IRF2 axis.


Asunto(s)
Leucemia Mieloide Aguda , MicroARNs , ARN Largo no Codificante , Animales , Ratones , MicroARNs/metabolismo , ARN Largo no Codificante/metabolismo , Línea Celular Tumoral , Factor 2 Regulador del Interferón/genética , Factor 2 Regulador del Interferón/metabolismo , Leucemia Mieloide Aguda/patología , Proliferación Celular/genética , Apoptosis/genética
SELECCIÓN DE REFERENCIAS
DETALLE DE LA BÚSQUEDA